Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Kansas: - Cancer Center of Kansas - Chanute — Chanute, Kansas
- Cancer Center of Kansas - Dodge City — Dodge City, Kansas
- Cancer Center of Kansas - El Dorado — El Dorado, Kansas
- University of Kansas Clinical Research Center — Fairway, Kansas
- Central Care Cancer Center - Great Bend — Great Bend, Kansas
Phase 3 Recruiting NIH
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in Kansas: - Central Care Cancer Center - Garden City — Garden City, Kansas
- Central Care Cancer Center - Great Bend — Great Bend, Kansas
- Cancer Center of Kansas-Wichita Medical Arts Tower — Wichita, Kansas
- Ascension Via Christi Hospitals Wichita — Wichita, Kansas
- Cancer Center of Kansas - Wichita — Wichita, Kansas
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Kansas: - University of Kansas Cancer Center — Kansas City, Kansas
- The University of Kansas Cancer Center - Olathe — Olathe, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Kansas: - Local Institution - 007-942-B — Chanute, Kansas
- Local Institution - 007-942-D — El Dorado, Kansas
- Local Institution - 007-942-E — Independence, Kansas
- Local Institution - 007-942-F — Kingman, Kansas
- Local Institution - 007-942-G — Liberal, Kansas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06881784
Sites in Kansas: - The University of Kansas Cancer Center — Westwood, Kansas
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Kansas: - Kansas University Medical Center — Westwood, Kansas
Phase 2 Recruiting Network
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Kansas: - University of Kansas Clinical Research Center — Fairway, Kansas
- University of Kansas Cancer Center — Kansas City, Kansas
- The University of Kansas Cancer Center - Olathe — Olathe, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
- Salina Regional Health Center — Salina, Kansas
Phase 2 Recruiting Industry
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% …
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT05609578
Sites in Kansas: - Local Institution - 017-820J — Fairway, Kansas
- Local Institution - 017-820A — Kansas City, Kansas
- Local Institution - 017-820B — Kansas City, Kansas
- Local Institution - 017-820C — Kansas City, Kansas
- Local Institution - 017-820H — Kansas City, Kansas
Phase 1, Phase 2 Recruiting Industry
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disea…
Sponsor: AbbVie
NCT ID: NCT06772623
Sites in Kansas: - Kansas City Cancer Center /ID# 273679 — Overland Park, Kansas
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Kansas: - The University of Kansas Cancer Center — Kansas City, Kansas
Phase 2 Recruiting Industry
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this stud…
Sponsor: Boehringer Ingelheim
NCT ID: NCT05882058
Sites in Kansas: - University of Kansas Cancer Center — Westwood, Kansas
Phase 1, Phase 2 Recruiting Industry
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT05361174
Sites in Kansas: - The University of Kansas Cancer Center — Westwood, Kansas
Phase 2 Recruiting Academic/Other
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% c…
Sponsor: University of Kansas Medical Center
NCT ID: NCT04992780
Sites in Kansas: - The University of Kansas Cancer Center, Westwood Campus — Kansas City, Kansas
- The University of Kansas Cancer Center, Overland Park Clinic — Overland Park, Kansas
- KUCC MCA- TUKHS, Saint Francis Hospital — Topeka, Kansas
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
Sponsor: University of Kansas Medical Center
NCT ID: NCT04467723
Sites in Kansas: - The University of Kansas Cancer Center (KUCC) — Fairway, Kansas
- The University of Kansas Cancer Center, Westwood Campus — Kansas City, Kansas
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Kansas: - The University of Kansas Cancer Center, Investigational Drug Services — Fairway, Kansas
- The University of Kansas Clinical Research Center — Fairway, Kansas
- The University of Kansas Hospital — Kansas City, Kansas
- The University of Kansas Medical Center Medical Office Building — Kansas City, Kansas
- University of Kansas Hospital Cambridge North Tower A — Kansas City, Kansas
Phase 1 Recruiting Industry
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
Sponsor: AstraZeneca
NCT ID: NCT06218914
Sites in Kansas: - Research Site — Westwood, Kansas
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Kansas: - Central Care Cancer Center - Garden City — Garden City, Kansas
- Central Care Cancer Center - Great Bend — Great Bend, Kansas
- Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
- Mercy Hospital Pittsburg — Pittsburg, Kansas
- Cotton O'Neil Cancer Center / Stormont Vail Health — Topeka, Kansas
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Kansas: - HaysMed — Hays, Kansas
- Lawrence Memorial Hospital — Lawrence, Kansas
- The University of Kansas Cancer Center - Olathe — Olathe, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
- University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
Recruiting Academic/Other
This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study. The study will also assess s…
Sponsor: Addario Lung Cancer Medical Institute
NCT ID: NCT06486428
Sites in Kansas: - Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html — Multiple Locations, Kansas